Edition:
United Kingdom

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

23.96USD
9:00pm BST
Change (% chg)

$0.61 (+2.61%)
Prev Close
$23.35
Open
$23.18
Day's High
$24.03
Day's Low
$22.63
Volume
103,028
Avg. Vol
76,763
52-wk High
$43.30
52-wk Low
$21.27

Chart for

About

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product... (more)

Overall

Beta: 2.40
Market Cap(Mil.): $1,919.56
Shares Outstanding(Mil.): 53.83
Dividend: --
Yield (%): --

Financials

  TBPH.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -4.62 -- --
ROI: -57.04 14.84 14.38
ROE: -82.78 16.34 16.07

BRIEF-Theravance Biopharma Q4 Revenue $4.5 Million

* THERAVANCE BIOPHARMA, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

27 Feb 2018

BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

29 Jan 2018

BRIEF-Theravance, Mylan Announce FDA Acceptance Of Marketing Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Source text for Eikon: Further company coverage:

29 Jan 2018

BRIEF-Theravance Biopharma ‍Files Supplemental NDA With U.S. FDA For Use Of Trelegy Ellipta​

* THERAVANCE BIOPHARMA HIGHLIGHTS SUBMISSION OF LANDMARK IMPACT DATA TO FDA TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA

28 Nov 2017

BRIEF-Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD

* Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD Source text for Eikon: Further company coverage:

16 Nov 2017

BRIEF-Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin

* Theravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease

13 Nov 2017

BRIEF-Theravance Biopharma posts Q3 loss of $1.27 per share

* Theravance biopharma, inc. Reports third quarter 2017 financial results and provides business update

07 Nov 2017

BRIEF-Theravance Biopharma and Mylan reports positive Phase 3 data for Revefenacin

* Theravance Biopharma and mylan report additional positive phase 3 data for Revefenacin (TD-4208) in multiple presentations at 2017 Chest Annual Meeting

01 Nov 2017

Competitors

  Price Chg
Merck & Co., Inc. (MRK.N) $59.41 -0.22
The Medicines Company (MDCO.OQ) $29.76 +1.36
GlaxoSmithKline plc (GSK.L) 1,436.80 +24.60
AstraZeneca plc (AZN.L) 4,992.00 +1.00
Novartis AG (NOVN.S) CHF76.10 +0.86

Earnings vs. Estimates